2025/11/30 by Neysimélia Costa Villela, Anita Frisanco Oliveira, Rafael Gonzales de Souza Ferreira +4 · 1 voice
Medicine · #Myeloproliferative Neoplasms: Diagnosis and Treatment #Acute Myeloid Leukemia Research #Multiple Myeloma Research and Treatments
paper · pdf · doi:10.46765/2675-374x.2025v6n1e290
openalex publication_date 2025/11/30 · openalex created_date 2025/11/30 · openalex updated_date 2026/07/22
Juvenile myelomonocytic leukemia (JMML) is a rare and distinctive hematologic neoplasm affecting infants and younger children. Hyperactivation of the RAS signaling pathway is a central initiating event in JMML, which also delineates its various genetic and clinical subtypes. While a small percentage of children may achieve spontaneous clinical remission, allogeneic hematopoietic cell transplantation (HCT) remains the only possible cure for most JMML patients. In this article, we reviewed the indications of HCT in JMML. Other myeloproliferative diseases, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are extremely rare in pediatrics and are briefly discussed.